The collaboration will expand EQRx's novel therapies pipeline, according to the two firms. Exsicienta will lead the discovery phase through investigational new drug (IND) filing, and EQRx will take on the clinical development, regulatory, and marketing efforts. They will share costs, they said.

MolDiscovery algorithm helps scientists find promising small molecules
A computer algorithm called molDiscovery uses mass spectrometry data from small molecules to predict the identity of unknown substances, potentially saving...

Nanoparticles may offer new way to tackle antibiotic-resistant bacteria
A team of researchers has developed nanoparticles that use a completely different mode of action from conventional antibiotics. These inorganic nanoparticles...

Hydrogen maps of SARS-CoV-2 main protease point to effective repurposed drugs
Scientists have used atomic maps of hydrogen atoms to determine that the SARS-CoV-2 main protease acts in unexpected ways when it comes into contact with...

Waters launches new small molecule mass spectrometer
Waters has released its new time-of-flight mass spectrometer, the Acquity RDa Detector, for small molecule analysis.

Vividion raises $135M for immuno-oncology small-molecule drugs
Vividion Therapeutics has raised $135 million in financing to support the development of its pipeline of precision oncology and immunology programs.